This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Prospective, Randomized, Three Arms, Open Label Study Comparing the Safety and Efficacy of Two Formulations of PP110 to the Active Comparator Preparation-H® Cream in the Treatment of Bleeding Hemorrhoids Grades 2-3

This study has been completed.
Information provided by (Responsible Party):
Peritech Pharma Ltd. Identifier:
First received: December 9, 2013
Last updated: June 1, 2014
Last verified: June 2014

Eligible patients with bleeding hemorrhoids of grade 2-3 are randomized to test-1 product (PP110 Gel), test-2 product (PP-110 medicated wipes) or control (Preparation-H cream).

Test product usage: once daily, about 1-5 minutes prior to first bowel movement. Control product usage: according to label, 3-4 times daily application to rectal region.

At the end of each day, subject fills a questionnaire regarding bleeding, pain, discharge, swelling, itching, discomfort and painkiller usage.

Treatment is for two weeks, after which subjects fill a feedback questionnaire addressing treatment efficacy and subject satisfaction. Also, at the end of two weeks, subjects are examined by study physician who assesses hemorrhoid severity.

Condition Intervention Phase
Bleeding Hemorrhoids Drug: PP110 Gel Drug: PP110 Medicated wipes Drug: Preparation-H Cream Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Peritech Pharma Ltd.:

Primary Outcome Measures:
  • Bleeding / Spotting [ Time Frame: 14 days ]

Secondary Outcome Measures:
  • Pain [ Time Frame: 14 days ]
  • Discharge [ Time Frame: 14 days ]
  • Itching [ Time Frame: 14 days ]
  • Swelling [ Time Frame: 14 days ]
  • Discomfort [ Time Frame: 14 days ]
  • Painkillers usage [ Time Frame: 14 days ]

Enrollment: 101
Study Start Date: November 2013
Study Completion Date: June 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PP110 Gel
PP110 Gel
Drug: PP110 Gel
Experimental: PP110 medicated wipes
PP110 Medicated wipes
Drug: PP110 Medicated wipes
Active Comparator: Preparation-H cream
Preparation-H cream
Drug: Preparation-H Cream


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18-70
  2. Bleeding hemorrhoids with / without pain
  3. Diagnosis of internal hemorrhoids of grade 2-3, or external bleeding hemorrhoids
  4. Signed Informed Consent

Exclusion Criteria:

  1. Known rectal sensitivity
  2. Rectal infection
  3. Grade IV hemorrhoids
  4. Use of anti-coagulants (except Aspirin or Plavix) within 30 days prior to enrollment
  5. Known inflammatory bowel disease
  6. Anal fissure
  7. Military personnel
  8. Female patients that are pregnant, or are not using a reliable method of birth control, or are nursing
  9. Patients who have been involved in another experimental trial within the past 30 days
  10. Patients presently diagnosed with cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02010099

Kfar Saba, Israel
Kiryat Ono, Israel
Modiin, Israel
Ramat-Gan, Israel
Tel-Aviv, Israel
Sponsors and Collaborators
Peritech Pharma Ltd.
Principal Investigator: Ehud Klein, Prof. Maccabi Healthcare Services, Israel
  More Information

Additional Information:
Responsible Party: Peritech Pharma Ltd. Identifier: NCT02010099     History of Changes
Other Study ID Numbers: PP110 01
Study First Received: December 9, 2013
Last Updated: June 1, 2014

Additional relevant MeSH terms:
Pathologic Processes
Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Vascular Diseases
Cardiovascular Diseases
Cryoprotective Agents
Protective Agents
Physiological Effects of Drugs
Dermatologic Agents
Cardiotonic Agents
Autonomic Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Nasal Decongestants
Respiratory System Agents
Adrenergic alpha-1 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents processed this record on September 20, 2017